Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757463 | 0.86 | TSHR (0.50) | TSHRCASP1CHRNA7ALDH1A1 | |
| SCHEMBL5097016 | 0.77 | TSHR (0.37) | TSHRCASP1 | |
| SCHEMBL5097019 | 0.75 | TSHR (0.40) | TSHRCASP1CHRNA7 | |
| SCHEMBL13459873 | 0.74 | — | — | |
| SCHEMBL3190316 | 0.74 | TSHR (1.00) | TSHRCASP1CHRNA7ALDH1A1 | |
| SCHEMBL3472303 | 0.74 | TSHR (1.00) | TSHRCASP1CHRNA7ALDH1A1 | |
| Cyclohexanone Oxime SCHEMBL37995 | 0.74 | — | — | |
| Cyclohexanone Oxime SCHEMBL11884936 | 0.74 | TSHR (1.00) | TSHRCASP1CHRNA7ALDH1A1 | |
| SCHEMBL3472281 | 0.74 | TSHR (1.00) | TSHRCASP1CHRNA7ALDH1A1 | |
| SCHEMBL3474721 | 0.74 | TSHR (1.00) | TSHRCASP1CHRNA7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439263-B2 | Pyrrolidine and thiazolidine compounds | LES LABORATOIRES SERVIER (FR) | 2008-10-21 | — | — | US | disclosed |
| US-20080119549-A1 | METABOLICALLY-STABILIZED INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON (NL) | 2008-05-22 | — | — | US | disclosed |
| EP-1598350-B1 | Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis | SERVIER LAB (FR) | 2007-07-11 | — | — | EP | disclosed |
| US-20050261501-A1 | Pyrrolidine and thiazolidine compounds | LES LABORATOIRES SERVIER (FR) | 2005-11-24 | — | — | US | disclosed |
| EP-1598350-A1 | Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis | LES LABORATOIRES SERVIER (FR) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119549-A1 | METABOLICALLY-STABILIZED INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ABHD6 | TSHR 2485/4885CASP1 2639/4885CHRNA7 2775/4885 |
| US-20050261501-A1 | Pyrrolidine and thiazolidine compounds | DPP4, DPP3, NR4A1 | TSHR 71/4885CASP1 1430/4885CHRNA7 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.